Are Antiplatelet Agents Beneficial in Essential Thrombocythemia? Maybe Yes, Probably No

Chu and colleagues' systematic review examined the benefits and risks of treating patients with essential thrombocythemia with antiplatelet agents. The editorialist discusses the uncertainty the review uncovers and the need for high-quality trials to definitively address this important clinical question.

http://ift.tt/2szZakI